Patent ID: 11858988
Assignee: GANYMED PHARMACEUTICALS GMBH
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A method of producing a single chain anti-CLDN6 antibody that binds to CLDN6, the method comprising the steps of:
a. culturing a host cell transformed with an expression construct comprising a nucleic acid sequence, said sequence encoding a polypeptide chain of a single chain anti-CLDN6 antibody comprising an antibody heavy chain variable region and an antibody light chain variable region under conditions in which the host cell expresses the single chain antibody; and
b. harvesting a preparation of the single chain antibody expressed by the cell;
wherein:
(i) the antibody heavy chain variable region comprises the heavy chain HCDR1, HCDR2, and HCDR3 regions of SEQ ID NO: 34 and the antibody light chain variable region comprises the light chain LCDR1, LCDR2, and LCDR3 regions of SEQ ID NO: 35,
wherein HCDR1 consists of amino acid sequence GYSFTGYT (SEQ ID NO: 47) identified within SEQ ID NO: 34, HCDR2 consists of amino acid sequence INPYNGGT (SEQ ID NO: 54) identified within SEQ ID NO: 34, and HCDR3 consists of amino acid sequence ARDYGYVLDY (SEQ ID NO: 55) identified within SEQ ID NO: 34, and wherein LCDR1 consists of amino acid sequence SSVSY (SEQ ID NO: 56) identified within SEQ ID NO: 35, LCDR2 consists of amino acid sequence STS (SEQ ID NO: 53) identified within SEQ ID NO: 35, and LCDR3 consists of amino acid sequence QQRSIYPPWT (SEQ ID NO: 57) identified within SEQ ID NO: 35;
(ii) the antibody heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 36 and the antibody light chain variable region comprises the amino acid sequence of SEQ ID NO: 37;
(iii) the antibody heavy chain variable region comprises the heavy chain HCDR1, HCDR2, and HCDR3 regions of SEQ ID NO: 38 and the antibody light chain variable region comprises the light chain LCDR1, LCDR2, and LCDR3 regions of SEQ ID NO: 39,
wherein HCDR1 consists of amino acid sequence GYSFTGYT (SEQ ID NO: 47) identified within SEQ ID NO: 38, HCDR2 consists of amino acid sequence INPYNGGI (SEQ ID NO: 60) identified within SEQ ID NO: 38, and HCDR3 consists of amino acid sequence ARDFGYVLDY (SEQ ID NO: 61) identified within SEQ ID NO: 38, and wherein LCDR1 consists of amino acid sequence SSVSY (SEQ ID NO: 56) identified within SEQ ID NO: 39, LCDR2 consists of amino acid sequence STS (SEQ ID NO: 53) identified within SEQ ID NO: 39, and LCDR3 consists of amino acid sequence QQRSTYPPWT (SEQ ID NO: 62) identified within SEQ ID NO: 39; or
(iv) the antibody heavy chain variable region comprises the heavy chain HCDR1, HCDR2, and HCDR3 regions of SEQ ID NO: 40 and the antibody light chain variable region comprises the light chain LCDR1, LCDR2, and LCDR3 regions of SEQ ID NO: 41,
wherein HCDR1 consists of amino acid sequence GYSFTGYT (SEQ ID NO: 47) identified within SEQ ID NO: 40, HCDR2 consists of amino acid sequence INPYNGGS (SEQ ID NO: 63) identified within SEQ ID NO: 40, HCDR3 consists of amino acid sequence ARDYGYVFDY (SEQ ID NO: 64) identified within SEQ ID NO: 40, LCDR1 consists of amino acid sequence SSVNY (SEQ ID NO: 65) identified within SEQ ID NO: 41, LCDR2 consists of amino acid sequence STS (SEQ ID NO: 53) identified within SEQ ID NO: 41, and LCDR3 consists of amino acid sequence QQRNNYPPWT (SEQ ID NO: 66) identified within SEQ ID NO: 41.